Cyllene Therapeutics, previously known as EG 427, has successfully secured €33 million in a Series C financing round. The funding was co-led by new investors GordonMD Global Investments and M Ventures, with continued support from existing partners. These proceeds are earmarked to advance the clinical development of its lead gene therapy candidate, EG110A, for severe neuro-urological conditions.
Strategic Rebranding and Investor Confidence
Coinciding with its financing, the company announced its rebranding to Cyllene Therapeutics, a name that honors its proprietary HERMES technology platform. This change reflects the biotech's evolution into a late-stage clinical company with an expanding global presence. The new identity connects the company's core science to its forward-looking mission in neurology.
The financing round saw strong backing from both new and established investors, signaling significant confidence in the company's direction. GordonMD Global Investments and M Ventures led the investment, joined by returning backers Andera Partners, Bpifrance Investissement, and Lamond Ventures. This robust financial support provides a solid foundation for the company's ambitious clinical and expansion plans.
Advancing a Novel Gene Therapy
The capital will primarily fuel the continued development of EG110A, a precision genetic medicine for neurogenic detrusor overactivity (NDO). This condition, often associated with spinal cord injuries, causes significant bladder control issues for patients. EG110A aims to provide a durable and targeted treatment by addressing the underlying neurological drivers of the disease.
At the core of Cyllene's approach is its unique HERMES platform, which utilizes a non-replicating herpes simplex virus-1 (nrHSV-1) vector. This technology is designed for the safe and targeted delivery of therapeutic DNA directly to specific neurons. The platform's large payload capacity and potential for repeat dosing make it a versatile tool for developing smarter DNA medicines.
Promising Early Clinical Results
Early clinical data for EG110A from an ongoing Phase 1/2 study has been highly encouraging. Patients treated with the therapy have shown substantial and sustained reductions in urinary incontinence episodes nine months after a single administration. These results provide preliminary validation for the treatment's potential to significantly improve patient quality of life.
The positive findings also support the company's scientific strategy of selectively targeting type C sensory neurons. This approach is believed to address the root cause of bladder overactivity with high precision. The therapy has demonstrated a strong safety profile, further bolstering confidence in its long-term viability and clinical promise.
Future Clinical and Pipeline Expansion
Looking ahead, Cyllene Therapeutics plans to initiate a pivotal Phase 2b/3 study for EG110A in 2027. This trial will further assess the therapy's dosing, safety, efficacy, and long-term durability. An accompanying observational study will monitor patients for up to five years to gather extensive long-term data.
Beyond its initial focus, the company intends to broaden the applications for both EG110A and its HERMES platform. Expansion plans include investigating EG110A for the more common condition of overactive bladder (OAB). Furthermore, the company aims to leverage its platform to develop new drug candidates for other major neurological indications, including chronic pain and migraine.
This €33 million financing and strategic rebranding mark a pivotal moment for Cyllene Therapeutics, solidifying its position as a leader in nrHSV-1 vector technology. The investment accelerates the development of EG110A and enables the expansion of its innovative HERMES platform into new therapeutic areas. Ultimately, this progress brings the company closer to delivering potentially transformative genetic medicines to patients suffering from debilitating neurological diseases.